// App-Quantinova.ai

169 : Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).

Researchers

Presenter

  • Karim Fizazi

Principal Investigators

  • Kim N. Chi

  • Johann Sebastian De Bono

  • Tracy McGowan

  • Nonko Pehlivanov

  • Robert Louis Charnas

  • Mary Beth Todd

  • Dana E. Rathkopf

  • Charles J. Ryan

  • Howard I. Scher

  • Neal D. Shore

  • Peter De Porre

  • Anil Londhe

  • Robert B. Montgomery

  • Leonard G. Gomella

  • Kurt Miller

Medical Centers

  • Janssen Research & Development, Beerse, Belgium

  • Janssen Research & Development, LLC, Raritan, NJ

  • Janssen Global Services, Raritan, NJ

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • University of Washington, Seattle, WA

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Carolina Urologic Research Center, Myrtle Beach, SCInstitut Gustave Roussy, University of Paris Sud, Paris, FranceJanssen Research and Development, Los Angeles, CA

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Janssen Research & Development, LLC, Horsham, PA

  • BC Cancer Agency, Vancouver, BC, Canada

  • Jefferson Medical College and Kimmel Cancer Center, Philadelphia, PA

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Janssen Scientific Affairs, Horsham, PA

Locations

  • Canada

  • Germany

  • United Kingdom

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved